Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.40 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.40 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ABL2 | P42684 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688271 | 1.00 | PPARG (0.46) | PPARGNFE2L2LMNAPTGS2CXCR2 | |
| SCHEMBL687781 | 0.98 | PPARG (0.45) | PPARGNFE2L2LMNAPTGS2CXCR2 | |
| SCHEMBL687782 | 0.98 | PPARG (0.45) | PPARGNFE2L2LMNAPTGS2CXCR2 | |
| SCHEMBL6457046 | 0.87 | KIF11 (0.46) | PPARGNFE2L2LMNACXCR2CXCR1 | |
| SCHEMBL6457049 | 0.87 | KIF11 (0.46) | PPARGNFE2L2LMNACXCR2CXCR1 | |
| SCHEMBL687780 | 0.85 | PPARG (0.45) | PPARGNFE2L2LMNAPTGS2CXCR2 | |
| SCHEMBL31051131 | 0.85 | PPARG (0.47) | PPARGNFE2L2LMNAPTGS2CXCR2 | |
| SCHEMBL687984 | 0.83 | PPARG (0.46) | PPARGNFE2L2LMNAPTGS2CXCR2 | |
| SCHEMBL687983 | 0.83 | PPARG (0.46) | PPARGNFE2L2LMNAPTGS2CXCR2 | |
| SCHEMBL6453964 | 0.81 | CXCR2 (0.37) | PPARGNFE2L2PTGS2CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606248-B1 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2012-02-29 | — | — | EP | claimed |
| US-7737139-B2 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2010-06-15 | — | — | US | claimed |
| US-20060258730-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE S.P.A. (IT) | 2006-11-16 | — | — | US | claimed |
| EP-1606248-B1 | SULFONIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2012-02-29 | — | — | EP | disclosed |
| US-7737139-B2 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2010-06-15 | — | — | US | disclosed |
| US-20060258730-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | DOMPE S.P.A. (IT) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258730-A1 | Sulfonic acids, their derivatives and pharmaceutical compositions containing them | CCR8, CCR1, CXCR1 | PPARG 117/4885NFE2L2 2296/4885LMNA 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.